Skip to main content
. 2012 Aug 14;7(8):e43244. doi: 10.1371/journal.pone.0043244

Figure 1. Effects of intragastric infusion of Olanzapine.

Figure 1

(Vehicle group n = 5, Olanzapine group n = 6). 1a: Glucose evolution before (t = 90 to t = 100) and during (t = 120 to t = 240) the intragastric infusion of Olanzapine infusion (3 mg/kg/h). Glycemia significantly increased after 60 min of Olanzapine infusion (*p<0.05, **p<0.001; ANOVA repeated measures; Time, p<0.001; Time * Group, p<0.001; Group, p = 0.001). 1b: Endogenous glucose production before (t = 90 to t = 100) and during (t = 120 to t = 240) intragastric Olanzapine infusion. No significant changes were observed (ANOVA repeated measures; Time, p = 0.426; Time * Group, p = 0.937; Group, p = 0.356). 1c: Corticosterone levels before (t = 90 to t = 100) and during (t = 120 to t = 240) intragastric Olanzapine infusion. Corticosterone levels are significantly higher in the Olanzapine group only at t = 220 (*p<0.05; ANOVA repeated measures; Time, p<0.001; Time * Group, p = 0.58; Group, p = 0.039). 1d: Plasma insulin levels before (mean of time points t = 90 and t = 100) and at the end (mean of time points t = 180 and t = 220) of the intragastric infusion of Olanzapine. No significant differences were detected (ANOVA repeated measures; Time, p = 0.601; Time * Group, p = 0.981; Group, p = 0.834). Vehicle-treated animals  =  white dots; Olanzapine-treated animals  =  black dots.